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This review evaluates the 
beneficial effects of lifestyle 
(including exercise and diet) 
and of statins by considering 
the strength of data for 
each individually and their combination. 
The focus is on those studies with ‘hard’ 
endpoints, namely cardiovascular events 
and/or mortality. This approach is similar 
to that which formed the basis of the 
2013 guidelines of the American College 
of Cardiology (ACC) and American Heart 
Association (AHA) which evaluate the 
relationship between statin therapy and the 
reduction in hard endpoints.[1] 
The major components of the beneficial 
lifestyle were first defined in two long-term 
studies on American health professionals 
– the Women’s and Men’s Health Studies 
(Fig.  1.)[2-4] Those lifestyle factors were non-
smoking (36% relative risk reduction in total 
deaths), exercise for ≥30  min daily (22%), 
ideal body weight (18%), an ideal diet (16%) 
and modest alcohol intake (9%). Mortality 
rose sharply as the number of risk factors 
increased. Lifestyle risk factors were cigarette 
smoking (ever), lack of physical activity 
(<30 min/day moderate- to vigorous-intensity 
activity), low diet quality (lowest three-fifths 
of healthy diet score), overweight (body mass 
index ≥25 kg/m2) and an alcohol intake of 0 
or ≥15  g/day. Diet and exercise are part of 
an overall pattern of healthy living applicable 
not only to privileged professionals but to all 
racial groups including the less affluent and 
those living in large cities.[5] 
Lifestyle: Exercise and 
dietary patterns
Exercise training: What can it do? 
While there are many benefits of regular 
exercise such as better subjective health and 
better sleep, a major benefit is countering 
cardiovascular disease (CVD). Thus, regular 
exercise can lower blood pressure (BP) in 
hypertensives by 11/8 mmHg.[6] This requires 
30 - 60 min of exercise 3 - 5 times per week 
at a moderate walking pace, which is as good 
as an intensive walking pace. Greater degrees 
of ambulatory activity provide an incremental 
benefit to those at high cardiovascular risk.[7] 
In patients with chronic heart failure, exercise 
training lessens mortality.[8] Experimentally, 
exercise training gives protection after 
experimental reinfarction.[9] 
Thorough cardiovascular assessment
The ability to undertake high levels of 
exercise such as marathon running, does 
not ensure protection from myocardial 
infarction or death.[10] Thus, the intention to 
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Fig. 1. All-cause, cardiovascular and cancer mortality over 24 years in the Women’s Health Study in 
relation to the number of risk factors present. Figure from Opie,[46] modified from data from Dam et al.[4] 
FORUM
169       March 2014, Vol. 104, No. 3
undertake intensive exercise training requires 
a medical history, blood lipids and an exercise 
electrocardiogram before starting.
Exercise reduces low-density lipoprotein 
cholesterol (LDL-C) 
Taking into account data from 11 major 
outcome studies, intense exercise would 
reduce the 10-year risk of a coronary heart 
disease (CHD) event from 5% to just under 
4%, while with statins, the greater LDL-C 
reduction would reduce the risk from 5% 
to about half that (2.5%).[11] The apparently 
unexplained aspect of these data is exactly 
how exercise reduces LDL-C. In part, the 
effect may be the result of other lifestyle 
changes often associated with intense 
exercise such as a better diet and weight 
loss, but the unexpected change specific to 
exercise is, surprisingly, that in the genome. 
Exercising the genome 
The explanation of why vigorous exercise 
promotes health independently of other 
lifestyle changes comes from studies on 
identical same-sex twins who were either 
persistently physically active or inactive 
throughout their lives.[12] Gene expression 
in adipose tissue and in skeletal muscle was 
quantified by nuclear magnetic resonance 
spectroscopy to yield the metabolome. The 
altered gene expression in the muscle of the 
active twins was associated with increased 
fatty acid oxidation, while in adipose tissue, 
fatty acid storage was decreased (Fig. 2). 
The major metabolic changes between active 
and inactive twins were that blood glucose 
was lower in the physically active twins 
(p<0.001), serum fatty acid composition 
shifted towards a less saturated profile, and 
lipoprotein subclasses towards lower very-
low-density lipoprotein (V-LDL) (p<0.001), 
all of which are associated with lower risks 
of CHD. Taken together, these data prove 
that intense lifelong exercise can on its own 
induce beneficial changes in the expression 
of the genome unassociated with any other 
lifestyle change. 
Food, diet and health
Food patterns and long-term weight loss 
There are strong links between food 
patterns (as opposed to calorie-restricted 
diets) and cardiovascular health. In the 
American health professionals studies, with 
participants eating their normal pattern 
of food, and not on any diet, weight gain 
was associated with eating potato chips, 
potatoes, meats, butter, refined grains, 
sweets and desserts.[13] Small amounts of 
weight loss were associated with regular 
eating of vegetables, nuts, whole grains, 
fruit and yoghurt. Among weight-gainers, 
the worst offenders were sugar-sweetened 
beverages and 100% fruit juices. These 
relatively small changes in weight play a 
modest role in cardiovascular prevention. 
Diets: low-fat, high-fat, low-carbohydrate 
and others 
It is important to distinguish between ‘diet’ in 
the sense of patterns of eating food and the 
usual weight-reducing diets; it is chiefly the 
former that will now be evaluated. The ideal 
trial should have sufficient statistical power to 
demonstrate which dietary pattern produces 
a clear endpoint difference in CVD and/or 
mortality. The 2-year Israeli study fell short of 
this ideal even though adherence rates were 
excellent.[14] Subjects were allocated to one of 
three diets: a low-fat diet, the Mediterranean 
diet, or a low-carbohydrate diet, which has 
much in common with the New Atkins diet.[14] 
Weight loss over 2 years was greatest on the low-
carbohydrate diet (4.7 kg from an initial 90 kg), 
while LDL-C fell most on the Mediterranean 
diet. This study illustrates that even 2 years 
of strict dietary adherence is insufficient to 
impact on cardiovascular endpoints, a recurring 
problem when evaluating diets.
The very-low-carbohydrate, high-protein, 
high-fat Banting diet is closely related to 
the Atkins diet.[15] It allows more attractive 
foods and has good data to show weight loss 
and decreased insulin sensitivity, but at the 
cost of increasing LDL-C.[16] However, there 
are no reports on major outcomes such as 
CVD and/or mortality. Indeed, as Noakes[17] 
points out, large, well-designed outcome trials 
are urgently needed to test this hypothesis. 
In contrast, the Japanese diet is high in 
carbohydrate, containing much rice and little 
fat, yet the Japanese live longer than others. 
Perhaps the accompanying fish is protective, 
or maybe the secret lies in eating slowly. 
Another new diet with beneficial metabolic 
changes, which include a decreased LDL-C, 
is the New Nordic Diet, which is high in 
fruit, vegetables, whole grains and fish.[18] It 
has the merit of reducing both body weight 
and BP in centrally obese individuals but so 
far lacks data on CVD reduction.[18] 
Though a wide variety of diets is 
proposed, most lack comparative data, do 
not consider what each diet can achieve 
in terms of weight loss (if needed), blood 
lipid patterns and projected cardiovascular 
benefits, while simultaneously ensuring 
good compliance. Dietary adherence is 
enhanced by enthusiastic input, attractive 
presentation and personal contact.[15]
Dietary patterns that reduce mortality
The Mediterranean diet reduces mortality 
by 25%, CHD deaths by 33%, and cancer by 
24%.[19] Its beneficial components are a high 
intake of vegetables, legumes, fruits and 
nuts, cereal, fish and monounsaturated fats, 
with small amounts of meat, poultry and 
high-fat dairy products. 
Two studies link specific components 
of the Mediterranean dietary pattern to 
decreased mortality. In the first, in persons at 
high cardiovascular risk, the Mediterranean 
diet was supplemented with either extra-
virgin olive oil or nuts. This reduced the 
incidence of major cardiovascular events 
and deaths.[20] Both nuts and olive oil 
possess cardioprotective qualities, albeit 
with differing mechanisms.[21] The second 
study narrowed down the specific beneficial 
component to nuts[22] as part of a lifestyle 
that increased physical activity, and fruit 
or vegetables, and avoided smoking and 
dietary red meat. While the overall data 
favour the Mediterranean dietary pattern, 
it seems simpler to add more nuts to the 
diet especially if that specifically decreases 
mortality. 
Diet plus exercise as part of a 
beneficial lifestyle
This combination accounted for 30% of the 
overall lifestyle benefits in the American 
health professionals studies (Table  1). Diet, 
exercise and not smoking would account 
for 58% of the benefit. Experimentally, 
the damage caused by a very high-fat diet 
in rodents was reduced by exercise, the 
Lifelong vigorous physical activity
Gene expression
Circulating
metabolites
LDL-C HDL-C
Superior metabolic protection
Fig. 2. Effects of persistent lifelong physical 
activity on the genomic pattern, which results 
in beneficial changes in circulating metabolites. 
For detailed proposals refer to Kujala et al.[12] 
Note, the beneficially decreased serum low-
density lipoprotein cholesterol (LDL-C) and 
increased high-density lipoprotein cholesterol 
(HDL-C) levels.
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proposed site of interaction being at the level 
of gastrointestinal hormones.[23] 
Is it all too complex? 
There are so many food and dietary choices, 
each with arguments in their favour, that our 
personal choice has been simplified to: ‘All 
the colours every day’, a brief but compelling 
message from an Italian nutritionist.
Evaluation of statin 
therapy 
Statins: Benefits predominate
There is no doubt that statins are effective 
in secondary prevention, e.g. after an acute 
coronary syndrome (ACS); however, a steep 
linear relationship exists between LDL-C 
levels and the 10-year CHD risk (Fig.  3). 
Thus, the higher the initial LDL-C, the 
greater the statin-induced reduction of 
CHD events. Under-dosing statin in this 
setting is a frequent error; doses should be 
at the upper end of the dose range to obtain 
maximal cardioprotection.[24]
The benefit of statins is less in primary 
prevention. Even at very high LDL-C levels 
(e.g. 5 mmol/l), the 10-year risk is only close 
to 5% (Fig. 3). Statins affect a risk reduction 
of about one-fifth for every 1 mmol/l drop 
in LDL-C.[25] Therefore, statins can reduce 
this risk by almost half. However, the closer 
the untreated LDL-C gets to 2.5  mmol/l, a 
threshold often recommended for introducing 
statin therapy, the less the absolute benefit, 
even though the relative cardiovascular 
benefit, expressed as the percentage decrease 
in risk, remains constant. 
Current ACC/AHA guideline 
recommendations 
Almost all patients with prior ACS events, 
and/or clinical atherosclerotic cardiovascular 
disease (ASCVD) or otherwise judged to be 
at high risk, such as those with diabetes, 
require a statin for secondary prevention. 
For primary prevention, the 2013 ACC/
AHA guideline recommendations for statin 
therapy cover are LDL-C in the range 1.8 
- 4.8  mmol/l (Table  2).[1] Higher LDL-C 
levels may need exclusion of hereditary lipid 
problems by a lipidologist. 
The four major groups that have been 
shown to derive benefit from statins are 
those:
• with clinical ASCVD, in patients <75 
years of age 
• with primary elevation of LDL-C of 
≥4.9 mmol/l
• with diabetes, in patients aged 40 - 75 
years with an LDL-C of 1.8 - 4.8 mmol/l, 
but without ASCVD
• without clinical ASCVD or diabetes with 
an LDL-C of 1.8 - 4.8  mmol/l and an 
estimated 10-year risk of ASCVD ≥7.5%
South African guidelines
The South African guidelines,[26] based on 
those of the European Society of Cardiology 
(ESC), recommend the assessment of risk 
in primary prevention using the updated 
Framingham risk charts. The four categories 
of the Framingham risk score refer to the 
10-year risk of any cardiovascular event. For 
the highest risk group (>30%), the LDL-C 
goal is 1.8 mmol/, for the 15 - 30% risk group 
it is 2.5 mmol/l, and for <15% risk the goal 
is 3 mmol/l.[26] 
Risk prediction is no easy matter 
Accurate risk prediction is difficult, whether 
the ACC/AHA or the ESC guidelines are 
used. A recent Lancet editorial pointed 
out that the levels of risk prediction by 
the new ACC/AHA guidelines are roughly 
double those observed in several major 
outcome trials, including the Women’s 
Health Study, the Physicians’ Health 
Study and the Women’s Health Initiative 
Observational Study (Fig.  1). Thus, up to 
50% of Americans apparently targeted by 
their new guidelines do not actually have a 
risk that exceeds 7.5%.[27] 
Table 1. The lifestyle beneficial ‘big five’*,†
Lifestyle big five
Protection from 
death, % (frequency)‡ Mechanism proposed
Non-smoking 28 (35) Protects arteries 
Exercise (≥30 min/day) 17 (22) Slows the heart, lowers BP
Ideal weight 14 (18) Avoids the toxic substances released 
from fat cells
Ideal diet 13 (16) High unsaturated fatty acids, high fruit 
and vegetables, less red meat
Modest alcohol 7 (9) Anti-stress, alcohol improves blood 
cholesterol patterns 
All five 79 (100)  
BP = blood pressure.
*Note that successful coping with stress is not listed and may be estimated at 20 - 25% of the total lifestyle beneficial pattern. 
†Table constructed from American health professionals studies.[2,4]
‡ Deaths from all causes, including heart, stroke and cancer. Values in brackets indicate the frequency of the five lifestyle 
factors listed.
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The most recent approach, derived from 
the Treating to New Targets (TNT) trial 
(N=10 001), gives 13 easy-to-measure clinical 
predictors: age; sex; smoking; diabetes 
mellitus; total cholesterol; HDL-C; systolic 
BP; history of myocardial infarction; 
coronary artery bypass grafting; congestive 
heart failure or abdominal aortic aneurysm; 
glomerular filtration rate; and treatment 
status (low- (10  mg) or high-dose (80  mg) 
atorvastatin). [28] When applying these factors 
in the Incremental Decrease in End Points 
Through Aggressive Lipid Lowering (IDEAL) 
trial (N=8 888), the model identified a group 
of 11.7% whose predicted 5-year number 
needed to treat (NNT) was ≤25 and a group 
of 41.9% whose predicted NNT was ≥50.[28] Of 
note, however, peripheral artery disease and 
stroke were not included.
Should low-risk CVD patients take a statin?
This remains an unresolved issue, the 
problem being that in clinical practice the 
level of risk is decided largely by the levels 
of LDL-C and not by clear clinical criteria. 
The current Cochrane review supports 
statin use for primary prevention even in 
patients at risk levels <10%.[29] The review 
found reductions in all-cause mortality, 
major vascular events and revascularisations 
with no excess of adverse events among 
people without evidence of CVD treated 
with statins. These data make a strong case 
for statins in primary prevention in selected 
patients with risk rates that merit therapy 
(see section on risk prediction). 
Could additional tests help the decision? 
Supporting the current concept that vascular 
inflammatory changes are fundamental to the 
development of atherosclerosis,[24] months of 
potent statin therapy reduced C-reactive 
protein (CRP) levels in association with 
decreased major adverse coronary events. [30] 
Thus, inflammation may be an important 
driver of residual cardiovascular risk in 
patients with coronary artery disease despite 
aggressive statin therapy. The advantage 
for South African doctors is that high-
sensitivity CRP and apolipoprotein  a can 
be measured easily.[26] In exceptional cases 
the accuracy of risk prediction may be 
improved by imaging techniques such 
as carotid ultrasound, coronary calcium 
scoring or computed tomography coronary 
angiography, which may detect preclinical 
atherosclerosis and thereby support the 
need for treatment.[26] 
Statin side-effect: Memory lost or 
improved? 
An anguished patient cried out: ‘Several 
people I know had terrible leg cramps when 
they took statins. I also read in the paper 
that statins can cause memory loss. My 
doctor wants me to start taking statins, but 
I’m scared. How real are these concerns?’[31] 
According to the Cochrane review,[29] few 
side-effects should be anticipated. However, 
two that often concern patients are memory 
loss and, especially in exercising patients, 
myalgia. 
At least some degree of memory loss is 
inevitable in the age group of many persons 
taking statins. Data from the large randomised 
controlled trials assessing the development of 
Table 2. The major current ACC/AHA guidelines[1] for statin indications taking the level of evidence into account
A. Must give
Class of recommendation I, level of evidence A:
•  Persons <75 years of age with clinical ASCVD, give high intensity dose; if not tolerated, give moderate dose
•  Persons 40 - 75 years of age with DM, without ASCVD and with an LDL-C 1.8 - 4.8 mmol/l, give moderate dose (Fig. 2) 
•  Primary prevention in adults 45 - 75 years of age, without ASCVD or DM and estimated 10-year ASCVD risk of ≥7.5% (Fig. 2) 
B. Reasonable to give
Class of recommendation I, level of evidence B:
•  Primary prevention in patients ≥21 years of age with an LDL-C ≥4.9 mmol/l; high dose, or if not tolerated, moderate dose 
•  Primary prevention in patients ≥21 years of age with an LDL-C 1.8 - 4.8 mmol/l and 10-year risk of ≥7.5% 
•  Genetic predisposition: No clear recommendation but include genetically high LDL-C ≥4.1 mmol/l, strong family history 
Class of recommendation IIA, level of evidence B: 
•  Patients ≥75 years of age with clinical ASCVD after considering the potential benefit v. potential adverse effects, drug-drug interactions and 
personal preference; give moderate to high dose
ASCVD = atherosclerotic cardiovascular disease; DM = diabetes mellitus; LDL-C = low-density lipoprotein cholesterol.
Statin
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Mitochondrial
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Cardiac: bene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Skeletal: adverse
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Intention to continue running
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Stop statin
Continue running
Continue statin
Switch to fast walking
Options
Fig. 4. Suggested algorithm for runners developing myalgia. For advantages of walking fast and intensely, 
refer to Jukema et al.[39] (CK = creatine kinase.)
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Alzheimer’s disease and memory loss are not yet available. Though 
initial analyses indicate that statins do not prevent Alzheimer’s disease, 
they have a significant beneficial effect on the mini-mental state 
30-point questionnaire test used to screen for cognitive impairment.[32] 
A meta-analysis of 16 studies focused on short- and long-term cognitive 
effects of statins found no short-term benefit with suggestion of a long-
term benefit in preventing dementia.[33] The anti-inflammatory effects 
of statins provide a plausible mechanism for these statin effects.[34] 
Statin side-effect: Myalgia 
Prominent among the statin side-effects are myalgia and muscular 
weakness, which may be associated with a rise in circulating 
creatine kinase (CK).[35] In order of increasing severity and decreasing 
incidence, the statin-induced muscle-related conditions are myalgia, 
myopathy with elevated CK levels with or without symptoms, and 
rhabdomyolysis. Statins may increase CK levels without decreasing 
average muscle strength or exercise performance. In one large study, 
only about 2% had myalgia that could be attributed to statin use.[35] At 
a cellular level, statins optimise cardiac mitochondrial function but 
impair skeletal mitochondrial function by inducing different levels of 
reactive oxygen species at these two sites. The level of exercise and/or 
dose of statin may need reduction if the severity of the pain is limiting 
exercise (Fig. 4). Coenzyme Q10 has no proven benefit.[35]
Myalgia should be balanced against the positive health benefits of 
statins beyond the cardiovascular, which include decreased adverse 
events in heart failure patients,[36] decreased atrial fibrillation, modest 
antihypertensive effects and reduced risks of malignancies.[35] 
Statins and new-onset diabetes 
The four major risk factors for developing diabetes are: metabolic 
syndrome; impaired fasting glucose; body mass index (BMI) ≥30 kg/ m2 
and glycated haemoglobin A1c >6%.[37] In a 5-year trial (N=17 603) in 
those with one or more risk factors, the use of 20 mg rosuvastatin daily 
was associated with a 39% reduction in the first occurrence of a major 
cardiovascular event (hazard ratio (HR) 0.61; p=0.0001) and a 28% 
increase in diabetes (HR 1.28; 95% confidence interval (CI) 1.07 - 1.54; 
p=0.01).[37] 
Overall, considering all statins, in 13 trials (N=91 140) statin therapy 
was associated with a 9% (95% CI 1.02 - 1.17) increased risk for 
incident diabetes.[38] Treatment of 255 patients with statins for 4 years 
resulted in only one extra case of diabetes.[38] This small absolute 
risk for new diabetes is more than outweighed by cardiovascular 
benefits.[39] Thus, in 17 080 patients high-dose statin therapy over 5 
years decreased ACS or death by 45% at the cost of 13.3% new-onset 
diabetes.[40] 
Most importantly, new-onset diabetes can be avoided if the patient 
has none or only 1/4 risk factors for new diabetes: fasting blood glucose 
>5.5 mmol/l; fasting triglycerides >1.7 mmol/l; BMI >30 kg/m2; and a 
history of hypertension. In those with 2 - 4 of these adverse factors, 
new-onset diabetes developed in 14%.[41] 
Which statins are least likely to cause new diabetes? Compared 
with pravastatin, which was not associated with new diabetes, the 
absolute risks were 26, 31 and 34 events per 1 000 years of therapy, 
respectively, for simvastatin, atorvastatin and rosuvastatin.[42] These 
are remarkably low risks. 
Statins in renal disease 
In patients with chronic kidney disease, including those receiving 
dialysis, statins reduce the risk of major cardiovascular events.[43] 
Lifestyle plus statins: Do they go 
together? 
This is an ideal combination for those with high LDL-C levels that 
do not respond to lifestyle changes alone or for those who have 
not received or are unlikely to follow advice about making lifestyle 
changes. For some, if not many, patients it may be easier to take one 
or two tablets each day than to find the time and determination to 
exercise regularly. Despite this, the attending medical practitioner 
should strongly recommend combining statins with lifestyle changes, 
including exercise.
In an observational study, both statins and exercise individually 
reduced the adverse outcomes of CVD. Their combined effects 
were additive (Table  3). In the least physically fit, no statin group, 
baseline total cholesterol was 6.0 mmol/l, with baseline LDL-C being 
Table 3. Interaction between varying degrees of exercise-induced fitness and statin treatment on mortality rates in dyslipidaemic 
US veterans[11]*
Category Total, N MET† group Deaths, % HR unadjusted HR fully adjusted p-value‡
Least fit
No statin 1 024 ≤5.0 52 1.22 1.35 <0.0001
Statin 1 060 ≤5.0 37 1.0 1.0 -
Moderately fit
No statin 1 154 5.1 - 7.0 34 0.81 1.02 0.81§
Statin 1 573 5.1 - 7.0 21 0.57 0.65 <0.0001
Fit
No statin 1 335 7.1 - 9.0 20 0.50 0.81 0.01
Statin 1 705 7.1 - 9.0 10 0.28 0.41 <0.0001
Highly fit
No statin 1 498 >9.0 13 0.27 0.53 <0.0001
Statin 694 >9.0  6 0.16 0.30 <0.0001
MET = metabolic equivalent of task; HR = hazard ratio.
*Data from Kokkinos et al.[10] (Tables 3 and 4).
†Measure of energy expenditure; 1 MET is the amount of energy required to sit quietly.
‡p-value for fully adjusted HRs.
§p-value not significant. 
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4  mmol/l. After statin treatment, total cholesterol was 4.1  mmol/l, 
and LDL-C was 2.6  mmol/l (p<0.0001). Before intense exercise, 
lipids levels were similar. After intense exercise training, values 
were: total cholesterol 5.1  mmol/l, with LDL-C being 3.6  mmol/l. 
The combination of high fitness (for definition, refer to Lee and 
Paffenbarger[45]) and statin treatment in patients yielded a substantial 
reduction in mortality risk than in those who were least fit and either 
taking statin or no statin (HR 0.30; p<0.0001). 
The major unresolved problem is that either exercise or statins can 
singly cause muscular symptoms with an elevation of serum CK.[35] 
There is, as yet, no clearly defined outcomes-based policy to deal with 
such symptoms. A reasonable practical approach is to assess the CK 
level, and if elevated, to reduce either the statin dose or the intensity 
of exercise to brisk walking (Fig. 4).[44,45] 
Conclusion
Both lifestyle changes and statin therapy and their combination have 
well-defined positive roles in the management of the patient who 
needs advice on cardiovascular health.
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